Inactive Instrument

Analyst Reco. TapImmune Inc. OTC Bulletin Board

Equities

Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	04-30	MT
Piper Sandler Adjusts Marker Therapeutics' Price Target to $1.50 From $3.50, Reiterates Overweight Rating	31/05/22	MT
Oppenheimer Adjusts Marker Therapeutics' Price Target to $5 From $8, Maintains Outperform Rating	17/02/22	MT
Roth Capital Downgrades Marker Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3	17/02/22	MT
MARKER THERAPEUTICS : Piper Sandler Starts Marker Therapeutics at Overweight with $6 Price Target	25/03/21	MT
MARKER THERAPEUTICS : Cantor Fitzgerald Initiates Marker Therapeutics at Overweight Rating With $6 Price Target	19/03/21	MT

No results for this search